Our Partners

Orexia has built unique partnerships with world leading organisations to support the discovery and development of novel therapeutics

  • Sosei Heptares

    Sosei Heptares is an international biopharmaceutical group focused on the discovery and early development of new medicines originating from our proprietary GPCR-targeted StaR® technology and structure-based drug design platform capabilities. We are advancing a broad and deep pipeline of novel medicines across multiple therapeutic areas, including CNS, immuno-oncology, gastroenterology, inflammation and other rare/specialty indications. Sosei

    Find out more

  • Schrodinger

    Schrödinger is transforming the way therapeutics and materials are discovered. Schrödinger has pioneered a physics-based software platform that enables discovery of high-quality, novel molecules for drug development and materials applications more rapidly and at lower cost compared to traditional methods. The software platform is used by biopharmaceutical and industrial companies, academic institutions, and government laboratories

    Find out more

  • X-Chem

    X-Chem, Inc. is a privately-owned drug discovery, science and technology company based in Waltham, Massachusetts. As pioneer of DNA-encoded chemical library (DEL) technology, the company’s mission is to leverage its market-leading DEL platform to discover small molecule leads against high-value therapeutic targets. DEL technology allows X-Chem’s partners to rapidly screen hundreds of billions of novel

    Find out more

  • Optinose

    Optinose (NASDAQ: OPTN) is a global specialty pharmaceutical company focused on serving the needs of patients cared for by ear, nose and throat (ENT) and allergy specialists. The innovative mechanism of action of the Optinose Exhalation Delivery system (EDS) technology is designed to enable broad, consistent drug delivery high and deep in the nasal passages,

    Find out more